The Economic Burden of Visual Impairment and Comorbid Fatigue: A Cost-of-Illness Study (From a Societal Perspective)

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PURPOSE. To investigate the burden of visual impairment and comorbid fatigue in terms of impact on daily life, by estimating societal costs (direct medical costs and indirect non–health care costs) accrued by these conditions. METHODS. This cost-of-illness study was performed from a societal perspective. Cross-sectional data of visually impaired adults and normally sighted adults were collected through structured telephone interviews and online surveys, respectively. Primary outcomes were fatigue severity (FAS), impact of fatigue on daily life (MFIS), and total societal costs. Cost differences between participants with and without vision loss, and between participants with and without fatigue, were examined by (adjusted) multivariate regression analyses, including bootstrapped confidence intervals. RESULTS. Severe fatigue (FAS ≥ 22) and high fatigue impact (MFIS ≥ 38) was present in 57% and 40% of participants with vision loss (n = 247), respectively, compared to 22% (adjusted odds ratio [OR] 4.6; 95% confidence interval [CI] [2.7, 7.6]) and 11% (adjusted OR 4.8; 95% CI [2.7, 8.7]) in those with normal sight (n = 233). A significant interaction was found between visual impairment and high fatigue impact for total societal costs (€449; 95% CI [33, 1017]). High fatigue impact was associated with significantly increased societal costs for participants with visual impairment (mean difference €461; 95% CI [126, 797]), but this effect was not observed for participants with normal sight (€12; 95% CI [ 527, 550]). CONCLUSIONS. Visual impairment is associated with an increased prevalence of high fatigue impact that largely determines the economic burden of visual impairment. The substantial costs of visual impairment and comorbid fatigue emphasize the need for patient-centered interventions aimed at decreasing its impact.
Original languageEnglish
Pages (from-to)1916-1923
Number of pages8
JournalInvestigative Ophthalmology and Visual Science
Volume59
Issue number5
DOIs
Publication statusPublished - 2018

Cite this

@article{eba68ec267354a94866caccac75e0a66,
title = "The Economic Burden of Visual Impairment and Comorbid Fatigue: A Cost-of-Illness Study (From a Societal Perspective)",
abstract = "PURPOSE. To investigate the burden of visual impairment and comorbid fatigue in terms of impact on daily life, by estimating societal costs (direct medical costs and indirect non–health care costs) accrued by these conditions. METHODS. This cost-of-illness study was performed from a societal perspective. Cross-sectional data of visually impaired adults and normally sighted adults were collected through structured telephone interviews and online surveys, respectively. Primary outcomes were fatigue severity (FAS), impact of fatigue on daily life (MFIS), and total societal costs. Cost differences between participants with and without vision loss, and between participants with and without fatigue, were examined by (adjusted) multivariate regression analyses, including bootstrapped confidence intervals. RESULTS. Severe fatigue (FAS ≥ 22) and high fatigue impact (MFIS ≥ 38) was present in 57{\%} and 40{\%} of participants with vision loss (n = 247), respectively, compared to 22{\%} (adjusted odds ratio [OR] 4.6; 95{\%} confidence interval [CI] [2.7, 7.6]) and 11{\%} (adjusted OR 4.8; 95{\%} CI [2.7, 8.7]) in those with normal sight (n = 233). A significant interaction was found between visual impairment and high fatigue impact for total societal costs (€449; 95{\%} CI [33, 1017]). High fatigue impact was associated with significantly increased societal costs for participants with visual impairment (mean difference €461; 95{\%} CI [126, 797]), but this effect was not observed for participants with normal sight (€12; 95{\%} CI [ 527, 550]). CONCLUSIONS. Visual impairment is associated with an increased prevalence of high fatigue impact that largely determines the economic burden of visual impairment. The substantial costs of visual impairment and comorbid fatigue emphasize the need for patient-centered interventions aimed at decreasing its impact.",
author = "Wouter Schakel and {van der Aa}, {Hilde P. A.} and Christina Bode and Hulshof, {Carel T. J.} and {van Rens}, {Ger H. M. B.} and {van Nispen}, {Ruth M. A.}",
year = "2018",
doi = "10.1167/iovs.17-23224",
language = "English",
volume = "59",
pages = "1916--1923",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
number = "5",

}

TY - JOUR

T1 - The Economic Burden of Visual Impairment and Comorbid Fatigue

T2 - A Cost-of-Illness Study (From a Societal Perspective)

AU - Schakel, Wouter

AU - van der Aa, Hilde P. A.

AU - Bode, Christina

AU - Hulshof, Carel T. J.

AU - van Rens, Ger H. M. B.

AU - van Nispen, Ruth M. A.

PY - 2018

Y1 - 2018

N2 - PURPOSE. To investigate the burden of visual impairment and comorbid fatigue in terms of impact on daily life, by estimating societal costs (direct medical costs and indirect non–health care costs) accrued by these conditions. METHODS. This cost-of-illness study was performed from a societal perspective. Cross-sectional data of visually impaired adults and normally sighted adults were collected through structured telephone interviews and online surveys, respectively. Primary outcomes were fatigue severity (FAS), impact of fatigue on daily life (MFIS), and total societal costs. Cost differences between participants with and without vision loss, and between participants with and without fatigue, were examined by (adjusted) multivariate regression analyses, including bootstrapped confidence intervals. RESULTS. Severe fatigue (FAS ≥ 22) and high fatigue impact (MFIS ≥ 38) was present in 57% and 40% of participants with vision loss (n = 247), respectively, compared to 22% (adjusted odds ratio [OR] 4.6; 95% confidence interval [CI] [2.7, 7.6]) and 11% (adjusted OR 4.8; 95% CI [2.7, 8.7]) in those with normal sight (n = 233). A significant interaction was found between visual impairment and high fatigue impact for total societal costs (€449; 95% CI [33, 1017]). High fatigue impact was associated with significantly increased societal costs for participants with visual impairment (mean difference €461; 95% CI [126, 797]), but this effect was not observed for participants with normal sight (€12; 95% CI [ 527, 550]). CONCLUSIONS. Visual impairment is associated with an increased prevalence of high fatigue impact that largely determines the economic burden of visual impairment. The substantial costs of visual impairment and comorbid fatigue emphasize the need for patient-centered interventions aimed at decreasing its impact.

AB - PURPOSE. To investigate the burden of visual impairment and comorbid fatigue in terms of impact on daily life, by estimating societal costs (direct medical costs and indirect non–health care costs) accrued by these conditions. METHODS. This cost-of-illness study was performed from a societal perspective. Cross-sectional data of visually impaired adults and normally sighted adults were collected through structured telephone interviews and online surveys, respectively. Primary outcomes were fatigue severity (FAS), impact of fatigue on daily life (MFIS), and total societal costs. Cost differences between participants with and without vision loss, and between participants with and without fatigue, were examined by (adjusted) multivariate regression analyses, including bootstrapped confidence intervals. RESULTS. Severe fatigue (FAS ≥ 22) and high fatigue impact (MFIS ≥ 38) was present in 57% and 40% of participants with vision loss (n = 247), respectively, compared to 22% (adjusted odds ratio [OR] 4.6; 95% confidence interval [CI] [2.7, 7.6]) and 11% (adjusted OR 4.8; 95% CI [2.7, 8.7]) in those with normal sight (n = 233). A significant interaction was found between visual impairment and high fatigue impact for total societal costs (€449; 95% CI [33, 1017]). High fatigue impact was associated with significantly increased societal costs for participants with visual impairment (mean difference €461; 95% CI [126, 797]), but this effect was not observed for participants with normal sight (€12; 95% CI [ 527, 550]). CONCLUSIONS. Visual impairment is associated with an increased prevalence of high fatigue impact that largely determines the economic burden of visual impairment. The substantial costs of visual impairment and comorbid fatigue emphasize the need for patient-centered interventions aimed at decreasing its impact.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85045095988&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29677352

U2 - 10.1167/iovs.17-23224

DO - 10.1167/iovs.17-23224

M3 - Article

VL - 59

SP - 1916

EP - 1923

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 5

ER -